Therapeutics Alliances was launched in 2013 to facilitate the translation of NYU’s academic biomedical research into successful industry collaborations with a focus on developing new therapeutics.

Our program was built on the legacies of drugs such as Remicade and Sutent, which were developed with licensed NYU Langone research and combined have helped treat millions of people.

A Resource for Industry, Investors, and Nonprofits

Therapeutics Alliances partners with biopharmaceutical companies, investors, and nonprofits interested in advancing drug discovery–related research from NYU Langone. Each project is advanced as akin to a single-asset biotechnology startup with the benefit of industry-grade resources such as our contract research organization and consultant network, project and alliance management, and alignment of de-risking activities with intellectual property strategies.